blue cross blue shield federal glp 1 coverage Why we are changing of GLP-1 drugs for weight loss The Employer Shift in Obesity

The trial established the IGF-1 axis as a clinical therapeutic target and supports the broader pharmacological rationale for IGF-1 receptor agonism, of which IGF-1 LR3 is one analog with extended pharmacokinetic properties

Thats a real and fairly consistent finding

After 68 weeks of once-weekly injections, patients who completed the higher 12 mg dose lost an average of 71.2 pounds

In addition, lactoferrin is included as a necessary stabilizing agent for the glutathione molecule, to prevent it from oxidizing and degrading into its parent amino acids, cysteine, glutamine and glycine

doi: 10.1177/1073858420975711 88 KannerAM

Bal M et al